Latest:
OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion
The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Miguel Martin, MD, PhD
Latest:
Dr. Martin on Provider Confidence With Biosimilars in Oncology
Miguel Martín, MD, PhD, professor of medicine at the Complutense University, and head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañon in Madrid, Spain, discusses provider confidence with biosimilars in oncology.
Mihaela C. Cristea, MD
Latest:
Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer
Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.
Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, is a professor of medicine and chief of the Division of Hematology, in the Leukemia Section, at the Sylvester Comprehensive Cancer Center, University of Miami Health System.
Latest:
Dr Sekeres on the Methods and Design of a Study Evaluating Smoking Implications in MDS
Mikkael A. Sekeres, MD, discusses the design of a study assessing the correlation between smoking intensity and genetic mutations in patients with MDS.
Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, is a professor of medicine and chief of the Division of Hematology, in the Leukemia Section, at the Sylvester Comprehensive Cancer Center, University of Miami Health System.
Latest:
Dr Sekeres on the Rationale for the FDA Approval of Momelotinib in Myelofibrosis
Mikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.
Milan Radovich, PhD
Latest:
Indiana University Researchers Find Precision Medicine Improves Outcomes
With the growing body of evidence supporting positive outcomes with the use of precision medicine–based approaches, academic cancer centers are increasingly incorporating genomic technology into standard clinical care.
Mitchel Hoffman, MD
Latest:
Dr. Hoffman on Research Regarding Neoadjuvant Chemo and Primary Debulking in Ovarian Cancer
Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.